Molecular 'nanogenerator' developed that can target cancer cells and destroy them

November 15, 2001

NEW YORK, November 15, 2001 - Researchers at Memorial Sloan-Kettering Cancer Center (MSKCC) have developed a molecular nanogenerator that releases a cascade of atomic fragments known as alpha particles on the inside of cancer cells. These nanogenerators consist of a single radioactive atom contained inside a molecular cage and attached to an antibody that homes in on cancer cells -- carrying the generator to the interior of those cells and destroying them. The results of this work are published in the November 16 issue of Science.

"We have found an effective way of containing and then delivering this highly potent element directly into cancer cells," said study senior author David A. Scheinberg, M.D., Ph.D., Chief of MSKCC's Leukemia Service and head of the Laboratory of Hematopoietic Cancer Immunochemistry at the Sloan-Kettering Institute.

The investigators tested the nanogenerators in cell culture in a variety of human cancer cell types: leukemia, lymphoma, breast, ovarian, neuroblastoma, and prostate. They found the nanogenerators could kill all these types of cancer cells at extremely low concentrations.

Dr. Scheinberg and colleagues also tested the treatment in two mouse models, one for prostate cancer and one for disseminated (widespread) lymphoma. Many of the animals had long-term survival, and all of them had their lives extended after a single treatment at a low dose. In addition, many of the mice with prostate cancer had their prostate-specific antigen (PSA) levels decrease to zero and most others had PSA levels that were reduced. PSA levels are a common measure of the presence of prostate cancer in humans.

The atom contained inside the nanogenerator is actinium-225. Actinium decays by giving off short-lived, high-energy alpha particles that blast through cancer cells and destroy their DNA and proteins. When actinium decays, it produces a series of three daughter atoms each of which gives off its own alpha particle. Each particle increases the chance that the cancer cell will be destroyed. "You get four times the punch from one atom," Dr. Scheinberg said.

Targeting the generator to the inside of the cancer cells also increases the treatment's effectiveness. "If the atom is sitting on the outside of the cell, the alpha particle can travel in any direction, and it kills the cell only a fraction of the time," explained Michael McDevitt, Ph.D., the study's lead author and a senior research scientist in Dr. Scheinberg's lab. "If the generator is inside the cell, every particle will be effective." In addition, keeping the generator inside the cell greatly reduces the possibility that the daughter atoms could float off and damage healthy cells.

Numerous developments in technology have made the new nanogenerators possible. "The idea of targeting radioactive metals to tumors was first demonstrated by us in 1981," Dr. Scheinberg said. "So it's taken us 20 years to get to this more effective and sophisticated method." A large part of this advance was the development of antibodies that target various types of tumor cells in humans. In addition, researchers were able to identify an appropriate atom, actinium (which has long enough half-life to allow doctors time to administer the drug after it has been manufactured) and secure a supply of it from the Department of Energy -- because it is a by-product of waste from nuclear power plants and weapons. Finally, the researchers found a molecular cage, such as one developed by the Dow Chemical Company, that would hold the actinium atom.

Dr. Scheinberg and his team plan to file an application with the Food and Drug Administration to begin trials in humans sometime next year. He says leukemia will most likely be the first cancer the nanogenerators are tested on, because his team has the most experience targeting those types of tumors. Although the mice treated with the drug seemed to experience no toxic side effects, the true test of whether this will become an effective therapy will not be known until those human trials begin, Dr. Scheinberg noted.
-end-
This research was supported by the Doris Duke Charitable Foundation, the National Institutes of Health, the CaPCure Foundation, the Lymphoma Foundation, the Cure for Lymphoma Foundation, the Gabrielle Rich Foundation, and the Pepsico Foundation.

Memorial Sloan-Kettering Cancer Center is the world's oldest and largest private institution devoted to prevention, patient care, research, and education in cancer. Our scientists and clinicians generate innovative approaches to better understand, diagnose and treat cancer. Our specialists are leaders in biomedical research and in translating the latest research to advance the standard of cancer care worldwide.

Memorial Sloan Kettering Cancer Center

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.